1. Fortis Healthcare:
This healthcare company jumped 5.4% in two trading sessions after announcing plans to acquire People Tree Hospital in Bengaluru. Fortis Healthcare is buying the 125-bed multi-speciality hospital for Rs 430 crore through its subsidiary, International Hospital.
Fortis plans to inject an additional Rs 410 crore over three years to expand the hospital. The deal includes an adjacent 0.8-acre land parcel, enabling the hospital to scale from 125 to over 300 beds. MD & CEO Ashutosh Raghuvanshi said, “The deal complements the company’s cluster-focused growth strategy in Bengaluru with an overall potential to scale up to over 1,500 beds across seven facilities over the next three years.”
In Q2FY26, revenue climbed 17.3% YoY, while net profit surged 82.4%, powered by its hospital business. Hospital revenue grew 19.3%, fueled by higher bed occupancy, and now makes up 85% of total revenue. Average revenue per bed also improved, thanks to a better speciality mix and strong oncology performance.
Looking ahead, Fortis’s expansion strategy focuses on adding beds within its existing strongholds. After adding 550 beds in H1FY26, the company targets another 400–500 beds in FY26 and 300–400 more in FY27, through existing facility upgrades. Key projects include capacity additions in Gurugram, Noida, and Greater Noida, with a new hospital planned for Lucknow.
The move earned a "Buy" upgrade from JM Financial, which set a target price of Rs 1,093. The brokerage highlights the hospital's location in a supply-strapped area of North-West Bengaluru, perfectly positioned to capture rising demand. Analysts forecast the hospital's revenue will nearly double to Rs 130 crore by FY27 from Rs 75 crore in FY25. They note that with a second tower operational, its contribution could reach Rs 600 crore and achieve healthy margins by FY32. For Fortis overall, revenue and EBITDA are projected to compound annually at 17% and 26% respectively, through FY28.
2. Phoenix Mills:
This realty stock gained 3% last week after ICICI Direct reiterated its ‘Buy’ rating with a higher target price of Rs 2,210, implying an upside of 19%. The brokerage expects demand at Phoenix Mills’ malls to remain firm during the festive and holiday period. Mall spending is growing at close to 20% a year, supported by higher footfalls.
The demand trend is supported by traction across major retail categories such as entertainment, fashion, and jewellery. A gradual shift toward premium brands has improved store performance and overall spending quality. Based on current trends, ICICI Direct expects the company to achieve its double-digit growth guidance for the ongoing financial year. This stable operating performance provides a base for long-term expansion.
Phoenix Mills plans to scale up its portfolio across retail, offices, and hotels over the coming years. New developments and expansion are expected to drive growth. The company’s balance sheet remains strong, supported by healthy cash flow and low debt. Lease renewals across properties also offer scope for higher rents without significant additional investment.
Recent financials underline this strength. In Q2FY26, revenue rose 22% YoY to Rs 1,115 crore, driven by a recovery in housing sales. Net profit jumped 39%, aided by new mall ramp-ups and tighter cost control in hotels. Looking ahead, Forecaster estimates revenue to rise about 10% in Q3FY26, with a net profit growth of over 40%.
Management sounds upbeat. CEO Varun Parwal said the company “plans to add 1–2 million square feet of retail space” each year, while retail head Rashmi Sen pointed to a stronger focus on experiential food and beverage offerings. CFO Kailash Gupta noted that the “average cost of debt has been cut by nearly 10%”, improving the company’s ability to fund growth while keeping finances stable.
3. Aadhar Housing Finance:
This housing finance company rose 1.3% on December 24 after CEO Rishi Anand said AUM is set to grow 20–22% this year, supported by government stimulus and demand from individuals buying homes to live in, rather than speculative purchases by investors focused on resale or rental. He added that H2 is shaping up better than H1, with momentum improving as the year progresses.
The company sees disbursement growth of over 20% in Q3. Asset quality remains stable, with gross NPAs guided at around 1.1% for FY26, improving from about 1.4% in H1. Management also said recent rate cuts will be passed on to customers by the end of the quarter, alongside a gradual easing in the cost of funds.
Anand said, “We see enough demand and balance sheet strength to sustain 20–22% growth over the next three years, which should help us double our AUM in about three and a half years.”
Separately, the Competition Commission of India (CCI) on November 7 approved Blackstone’s plan to acquire up to 80.2% stake in Aadhar Housing Finance. Analysts say the move could improve access to capital, strengthen governance, and increase competition as global investors step up exposure to Indian housing finance.
Trendlyne’s Forecaster expects Aadhar Housing Finance’s net profit to rise 19.6% to Rs 1,091 crore in FY26, with revenue growing 31.2%. The stock appears in a screener of companies with expensive valuations, as its price-to-earnings (PE) ratio is above the industry average.
ICICI Direct has a ‘Buy’ rating on Aadhar Housing Finance with a target price of Rs 600. The brokerage highlights the company’s stable performance and disciplined lending, and expects the company to deliver 20% annual growth despite industry challenges.
4. Granules India:
The stock of this pharmaceutical company rose by over 6% in the past week after its board approved a massive fundraising plan. The company aims to raise up to Rs 1,462.5 crore through 2.5 crore convertible warrants priced at Rs 585 each, alongside an additional Rs 300 crore via the issue of 51.3 lakh equity shares to non-promoter investors.
Adding to the momentum, the company received tentative USFDA approval on December 22 for its Amphetamine tablets, which target attention-deficit hyperactivity disorder (ADHD), a market valued at $172 million. CMD Krishna Prasad Chigurupati noted that this move “strengthens Granules’ US generics portfolio” and underscores their commitment to “complex dosage forms and value-driven healthcare solutions.”
The company's financial health showed a significant turnaround in Q2, posting a net profit of Rs 120.6 crore compared to a loss of Rs 41.4 crore in the same period last year. This recovery was fueled by strong performance in North America and 7% sequential growth in the formulations business.
Trendlyne’s Forecaster projects its net profit to grow by 7.4% in Q3FY26 as the company continues to invest in R&D and its CDMO segment. The stock appears in a screener of companies that have shown relative outperformance as compared to the industry over the past month.
Management confirmed that its CDMO platform, which it established through its 2025 acquisition of Senn Chemicals AG, is now fully operational, supported by R&D integration with IIT Hyderabad. The platform is expected to hit profitability by Q4FY26. It also expects 1-2 approvals in controlled substance formulations within 2-3 years.
ICICI Direct has maintained a ‘Buy’ rating on the stock with a target price of Rs 660. The brokerage highlighted the acquisition of Senn Chemicals AG, which has opened new revenue streams in peptide development, though it cautioned that pricing pressures in the US and other regulated markets remain a potential risk.
5. GE Vernova T&D India (GE T&D):
This industrial machinery firm climbed 7.4% over the past week after securing a 2,500-megawatt (MW) power transmission order from AESL Projects. Power Grid Corporation of India estimates the project cost at about Rs 19,000 crore. Under the contract, GE T&D will set up a terminal station to transmit power from Khavda to South Olpad.
Earlier, on December 17, the company also won a maintenance order from Power Grid to refurbish the 2*500 MW transmission lines at Chandrapur, strengthening its position in high-voltage transmission upgrades.
Commenting on opportunities in transmission & distribution, MD & CEO Sandeep Zanzaria said, “The government plans to add up to 136 GW of hydro, pumped storage and conventional capacity by 2035, and nearly 100 GW of nuclear capacity by 2047.” He noted that every new power plant needs new transmission lines, which creates steady demand for the industry.
To capitalise on this opportunity, GE T&D plans a Rs 800 crore capex over the next three years. This investment will go towards expanding manufacturing capacity at its Vadodara, Padappai, and Hosur plants to meet rising demand from home and abroad.
In Q2FY26, the company reported strong operational performance. Revenue rose 40% YoY on improved execution across domestic and export orders, while net profit surged 107%. The sharp profit growth reflected a richer product mix and lower employee costs. Both revenue and profit beat Forecaster estimates by a wide margin.
Yes Securities initiated coverage on GE T&D with an ‘Add’ rating and a target price of Rs 3,200. The brokerage highlights Europe—now contributing about 35% of revenue—as a key driver of export growth, noting that local equipment suppliers are operating at near-full capacity. It expects transformer capacity additions to remain elevated through FY29. The analysts project revenue and net profit CAGRs of 30% and 39% over FY26-28.
Trendlyne's analysts identify stocks that are seeing interesting price movements, analyst calls, or new developments. These are not buy recommendations.
